Nasdaq
$9.95▲ 1.48%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $588.2MShares out 59.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 10.13After-hours26.10.14 05:244Ownership#●●●
ZEVRA THERAPEUTICS, INC.
Insider Neil F. McFarlane of Zevra Therapeutics reported a change in beneficial ownership of securities as of October 10, 2026. This filing serves as a standard Form 4 disclosure regarding insider stock transactions.…more
$9.95+1.48%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13Pre-market26.10.13 21:22144Ownership
ZEVRA THERAPEUTICS, INC.
Neil F. McFarlane of Zevra Therapeutics, Inc. has filed an SEC Form 144 to report the proposed sale of company shares. This filing serves as a notice of an insider's plan to dispose of their holdings.…more
$9.95+1.48%vs prev closeView filingShare - 8.17After-hours26.08.18 05:324Ownership
ZEVRA THERAPEUTICS, INC.
Insider Rahsaan Thompson of Zevra Therapeutics executed a transaction involving company stock on August 14, 2026, and reported it via Form 4. This filing formalizes the changes in the executive's beneficial ownership, which investors should monitor.…more
$9.95+1.48%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.20 20:30#●●●#●●●
Zevra Therapeutics Announces Q3 2026 Earnings Call Date
Zevra Therapeutics will report its financial results for the third quarter of 2026 after the market closes on November 3. The company will also host a conference call to discuss its corporate and financial performance.…more
$9.95+1.48%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.2Pre-market26.09.02 20:30
●●●●●●●● ●●●●● ●●●●●●
Zevra Therapeutics announced that its executive leadership team will present at several upcoming healthcare investor conferences in September. These sessions are standard corporate presentations and do not involve new material financial or operational disclosures.…more
$9.95+1.48%vs prev close - 8.25Pre-market26.08.25 20:30
●●●●●●●● ●●●●● ●●●●●●
Zevra Therapeutics presented new real-world data at the SSIEM symposium, demonstrating the sustained safety and efficacy of MIPLYFFA in treating Niemann-Pick disease type C. The findings highlight consistent disease stabilization across diverse patient populations over long-term treatment periods.…more
$9.95+1.48%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report